#Ireland #ALS #Belfast #Cumulus Neuroscience #NeuLogiq

Cumulus Neuroscience Unveils Promising Study Results in Scientific Reports

Cumulus Neuroscience, an international digital health company, has made significant strides in the assessment of cognitive function for those living with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The recent publication of their study in Scientific Reports, which showcases the efficacy of the NeuLogiq® platform, marks a pivotal moment in enhancing patient care and clinical trials in neurology.

Overview of the Study

The CNS-102 study stands out as the first of its kind to demonstrate that the NeuLogiq® platform can be successfully implemented at home for patients suffering from motor and cognitive impairments caused by these devastating conditions. The findings suggest that 82% of ALS patients found the platform user-friendly, while 75% expressed a positive overall opinion about the technology after an eight-month evaluation.

This research addresses a crucial gap in traditional clinical assessments, which primarily focus on motor function, thus falling short in capturing the cognitive, behavioral, and physiological changes associated with ALS and FTD. The authors contend that the alliance of at-home assessments using EEG technology with multi-domain cognitive evaluations is vital for a more comprehensive understanding of these diseases.

Methodology

The study involved 28 participants: 11 individuals with ALS, 7 with FTD, and 10 healthy controls. Over the course of eight months, participants underwent a mix of baseline neuropsychological evaluations at clinical settings and bi-weekly NeuLogiq sessions at home. The system employed a wireless 16-channel EEG headset coupled with a tablet-based application featuring gamified neurocognitive tasks, covering multiple domains such as executive functions, memory, language, social cognition, and psychomotor speed.

Key Findings

The usability of the NeuLogiq® platform was rated highly, with participants from all groups, especially those with ALS, reporting an average System Usability Scale (SUS) score indicating excellent ease of use. The study’s exploratory longitudinal analysis revealed trends suggesting the potential of frequent, multi-modal sampling at home to uncover changes, such as word fluency and facial emotion recognition, which were not detected in the less frequent in-clinic assessments. This illustrates the platform’s capability to monitor cognitive decline more effectively compared to traditional methods.

Expert Insights

According to Dr. Brian Murphy, the founder and Chief Scientific Officer at Cumulus Neuroscience, “This peer-reviewed publication represents a significant step forward, providing evidence that our gamified home assessments can accurately differentiate between patient groups effectively.” He added that this innovative approach could reshape clinical paradigms and support drug development processes by generating more sensitive data.

Professor Orla Hardiman from Trinity College Dublin echoed this sentiment, emphasizing that the CNS-102 study illustrates the validity and acceptance of at-home assessments, highlighting the urgent need for more sensitive and tailored measurement criteria in future ALS and FTD clinical trials.

Conclusion

The promising results from the CNS-102 study not only showcase the feasibility of the NeuLogiq® platform for at-home cognitive assessments but also signify a shift towards more inclusive and effective evaluation methods for neurological diseases. Cumulus Neuroscience aims to continue pushing the boundaries in digital health, providing stakeholders with crucial insights that could ultimately lead to breakthrough treatments for ALS and FTD.

For further information about Cumulus Neuroscience and their pioneering work, visit www.cumulusneuro.com.